Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE9A | O76083 | 20/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12710294 | 0.86 | PDE9A (0.72) | PDE9A | |
| SCHEMBL12733274 | 0.85 | PDE9A (0.72) | PDE9A | |
| SCHEMBL7886935 | 0.84 | PDE9A (1.00) | PDE9A | |
| SCHEMBL7882542 | 0.83 | PDE9A (1.00) | PDE9A | |
| SCHEMBL7877685 | 0.83 | PDE9A (1.00) | PDE9A | |
| SCHEMBL7876909 | 0.83 | PDE9A (1.00) | PDE9A | |
| SCHEMBL7876055 | 0.83 | PDE9A (0.84) | PDE9A | |
| SCHEMBL12399465 | 0.82 | PDE9A (0.82) | PDE9A | |
| SCHEMBL7879280 | 0.82 | PDE9A (0.82) | PDE9A | |
| SCHEMBL7884524 | 0.82 | PDE9A (1.00) | PDE9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110082137-A1 | NEW COMPOUNDS FOR THE TREATMENT OF CNS DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110082137-A1 | NEW COMPOUNDS FOR THE TREATMENT OF CNS DISORDERS | CHRM1, CHRM2, CHRM5 | PDE9A 1390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.